Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine

NAD+激酶 烟酰胺腺嘌呤二核苷酸 医学 不利影响 药理学 安慰剂 重症监护医学 烟酰胺磷酸核糖转移酶 生物信息学 叙述性评论 内科学 烟酰胺 观察研究 梅德林 临床试验 辅因子 系统回顾
作者
Abdulrahman Alangari,Jamal Mohammad Arif,Fahd Al Qureshah,Fahad Alkhodairy
出处
期刊:Frontiers in aging [Frontiers Media]
卷期号:7: 1887175-1887175
标识
DOI:10.3389/fragi.2026.1887175
摘要

Background Nicotinamide adenine dinucleotide (NAD + ) is a major coenzyme critically involved in cellular metabolism, mitochondrial function, DNA repair, and stress-response signaling. Age-associated decline in NAD + levels has generated interest in NAD + -augmenting strategies; however, recent large-scale human data indicate that whole-blood NAD + concentrations do not decline with healthy aging per se . Despite increasing commercial use of IV NAD + therapy in wellness settings, the clinical evidence supporting its efficacy and long-term safety remains limited. Methods Literature published between January 2018 and March 2026 was identified via PubMed and Google Scholar searches. Search terms were applied symmetrically across all target compounds and administration routes. Studies were included if they reported human clinical data on IV NAD + or IV NAD + precursor administration, or if they provided directly relevant mechanistic or safety evidence. Mechanistic and foundational studies published before 2018 were selectively incorporated via citation tracking of key included articles. Results Available human evidence is sparse and consists primarily of small uncontrolled studies, observational investigations, and isolated case reports. Short-term IV NAD + or NMN administration has been associated with transient increases in circulating NAD + levels and changes in selected biomarkers related to oxidative stress, inflammation, and cellular metabolism. Limited exploratory reports have also described self-reported improvements in sleep-related outcomes and neurologic symptoms. However, the clinical significance of these findings remains uncertain due to small sample sizes, lack of placebo controls, heterogeneous methodologies, and short follow-up durations. Reported adverse effects include nausea, cramping, flushing, and chest discomfort, while long-term safety data are lacking. Conclusion Current evidence regarding IV NAD + therapy remains preliminary and insufficient to support routine clinical or wellness use. Although mechanistic and translational studies provide biological rationale for NAD + augmentation, robust conclusions regarding efficacy, durability of benefit, optimal dosing, and long-term safety cannot currently be established. Larger randomized controlled trials with standardized protocols and clinically meaningful endpoints are required before IV NAD + therapy can be considered evidence-based clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
典雅翅膀发布了新的文献求助10
1秒前
英俊的铭的应助被日薪月亿采纳,获得10
1秒前
wanci的应助被舒心魂幽采纳,获得10
1秒前
Luo完成签到 ,获得积分10
2秒前
小丁发布了新的文献求助10
2秒前
3秒前
3秒前
淡淡晓露发布了新的文献求助10
3秒前
程破茧完成签到,获得积分0
4秒前
4秒前
5秒前
5秒前
喜洋洋完成签到 ,获得积分10
6秒前
6秒前
6秒前
6秒前
局外人发布了新的文献求助10
7秒前
7秒前
慕青的应助被Ami采纳,获得10
8秒前
热心市民小红花的应助被Lily采纳,获得10
8秒前
fsxadada123发布了新的文献求助10
8秒前
8秒前
耳东陈发布了新的文献求助10
8秒前
情怀的应助被淡然的尔云采纳,获得10
8秒前
8秒前
8秒前
白开水发布了新的文献求助10
8秒前
苏喜财完成签到,获得积分10
8秒前
8秒前
徐凯丽发布了新的文献求助10
8秒前
科目三的应助被刘山雨采纳,获得10
9秒前
9秒前
9秒前
小马甲的应助被Sylvia采纳,获得10
9秒前
9秒前
领导范儿的应助被有点意思采纳,获得10
9秒前
胡高照完成签到,获得积分10
9秒前
10秒前
10秒前
深情安青的应助被DuanJN采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817